Question

A 60-year-old with ASCVD and fasting TG 210 mg/dL on statin with LDL-C at goal asks about additional LDL-lowering with inclisiran. According to ACC 2022, which statement is correct?

Accepted Answer

Inclisiran is a small-interfering RNA dosed twice yearly to lower LDL-C

Answer

Inclisiran is an oral daily PCSK9 inhibitor

Answer

Inclisiran raises LDL-C

Answer

Inclisiran is indicated only for triglyceride lowering

Answer

Inclisiran replaces statins

Practice question

A 60-year-old with ASCVD and fasting TG 210 mg/dL on statin with LDL-C at goal asks about additional LDL-lowering with inclisiran. According to ACC 2022, which statement is correct?